Given the similarity of the chemotherapy backbone used in our study and the KEYNOTE-522 trial, the impact of EGFR-targeted therapy on the tumor microenvironment, as well as the non-overlapping mechanisms of action and toxicity profiles of pembrolizumab and panitumumab, it would be interesting to determine if panitumumab augments the efficacy of the KEYNOTE-522 regimen in a future clinical trial. This evidence concerns the gene EGFR and neoplasm.